A Long-term Safety Study of Duloxetine Hydrochloride in the Treatment of Japanese Children and Adolescents With Depressive Disorder
Latest Information Update: 06 May 2022
At a glance
- Drugs Duloxetine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Shionogi
- 01 Apr 2022 Results published in the Journal of Child and Adolescent Psychopharmacology
- 03 Aug 2020 Status changed from active, no longer recruiting to discontinued.
- 18 Jun 2020 Planned End Date changed from 10 Jun 2020 to 3 Jul 2020.